Novel brain targeting preparation for preventing and treating neurodegenerative disease

Abstract

The invention provides a novel brain targeting preparation for preventing and treating a neurodegenerative disease. The novel brain targeting preparation comprises effective dose of fusion protein of cell growth factor and TAT (transcriptional activator) cell-penetrating peptide, or fusion protein of the cell growth factor, TAT and a transferrin receptor monoclonal antibody, a protein activity protecting agent, and proper auxiliary material, wherein the fusion protein of cell growth factor and TAT cell-penetrating peptide or the fusion protein of the cell growth factor, TAT and transferrin receptor monoclonal antibody is an active ingredient. The novel brain targeting preparation disclosed by the invention has excellent performance of breaking through a blood brain barrier, and is specifically targeted to the brain; the defect that single TAT does not have cell selectivity can be overcome; a brain neurons microenvironment is regulated and controlled by the effects of neurotrophy, paracrine and the like, so as to play the roles of preventing and treating the neurodegenerative disease. The novel brain targeting preparation can be prepared into a freeze-drying preparation, a liquid preparation or an adhesive preparation and applied in an intravenous injection or nasal delivery manner.

Description

technical field [0001] The present invention relates to a novel brain-targeting preparation for preventing and treating neurodegenerative diseases, specifically, the brain-targeting preparation comprises an effective amount of fusion protein of cell growth factor and TAT penetrating peptide or cell growth factor and Fusion protein of TAT and transferrin receptor monoclonal antibody, protein activity protector and suitable auxiliary materials, wherein the fusion protein of cell growth factor and TAT penetrating peptide or cell growth factor and TAT and transferrin receptor monoclonal The fusion protein of the antibody is the active ingredient. The brain-targeting preparation can be prepared into a freeze-dried preparation, a liquid preparation or an adhesive preparation for intravenous injection or nasal administration. Background technique [0002] Neurodegenerative disease (Neurodegenerative disease, ND) is a group of chronic progressive neurological diseases based on prim...

AI Technical Summary

Problems solved by technology

Compared with the research on the systemic therapeutic effect of nasal administration entering the systemic circulation, the research on nasal administration targeting the central nervous system is still in the exploratory stage, such as the mechanism of action is still immature, and there is a lack of different animal (rat, dog, sheep). , monkeys) and between animals and humans; it is still in its infancy in terms of formulations, and only a few preparations are used in clinical practice, such as Pharmacia's nicotine for alternative smoking cessation, Sandoz's for Dihydroergotamine nasal preparation for treating migraine

Images